• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体内3H标记寡核苷酸的生物分布与代谢。I. 磷酸二酯和硫代磷酸酯的比较。

Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.

作者信息

Sands H, Gorey-Feret L J, Cocuzza A J, Hobbs F W, Chidester D, Trainor G L

机构信息

DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880.

出版信息

Mol Pharmacol. 1994 May;45(5):932-43.

PMID:8190109
Abstract

Biodistribution and metabolism of oligonucleotides were determined using a 3H-labeled 20-nucleotide phosphodiester and its phosphorothioate analog. The oligonucleotides were radiolabeled by 3H-methylation of an internal deoxyctidine with HhaI methylase and S- [3H]adenosylmethionine. Biodistribution studies were conducted after intravenous injection of 6 mg/kg (5 muCi) oligonucleotide. Metabolism of the oligonucleotides was determined by paired-ion high performance liquid chromatography. After phosphodiester injections, radiolabel rapidly cleared the blood. Relative initial concentrations were as follows: kidney > blood > heart > liver > lung > spleen. Radiolabel in spleen peaked at 1 hr and remained elevated for 24 hr. At 2 hr the concentration in all organs, except spleen, was equal to that in blood. High performance liquid chromatographic analysis of the kidney, liver, and spleen extracts and urine indicated extremely rapid metabolism to monomer. Results of studies after the injection of phosphorothioate oligonucleotide differed from those using the phosphodiester. Despite its rapid clearance from blood, phosphorothioate accumulated rapidly in all tissues, especially the kidney. Kidney uptake increased over time, remaining very high for 24 hr. Ratios of organ to blood concentrations at 2 hr for all organs were 5:1 or greater. Kidney and liver ratios were 84:1 and 20:1, respectively. Analysis of the kidney and liver extracts and urine indicated that slow metabolism occurred. These data suggest that phosphodiester oligonucleotides would have limited therapeutic utility. The stability and organ distribution of the phosphorothioate oligonucleotide imply that such oligonucleotides may have therapeutic potential.

摘要

使用3H标记的20核苷酸磷酸二酯及其硫代磷酸酯类似物测定寡核苷酸的生物分布和代谢。寡核苷酸通过用HhaI甲基化酶和S-[3H]腺苷甲硫氨酸对内部脱氧胞苷进行3H甲基化进行放射性标记。静脉注射6mg/kg(5μCi)寡核苷酸后进行生物分布研究。寡核苷酸的代谢通过离子对高效液相色谱法测定。注射磷酸二酯后,放射性标记迅速从血液中清除。相对初始浓度如下:肾脏>血液>心脏>肝脏>肺>脾脏。脾脏中的放射性标记在1小时达到峰值,并在24小时内保持升高。在2小时时,除脾脏外,所有器官中的浓度与血液中的浓度相等。对肾脏、肝脏和脾脏提取物以及尿液的高效液相色谱分析表明,其代谢极其迅速,生成单体。注射硫代磷酸酯寡核苷酸后的研究结果与使用磷酸二酯的结果不同。尽管其从血液中迅速清除,但硫代磷酸酯在所有组织中迅速积累,尤其是在肾脏中。肾脏摄取随时间增加,在24小时内一直保持很高。所有器官在2小时时的器官与血液浓度比为5:1或更高。肾脏和肝脏的比例分别为84:1和20:1。对肾脏和肝脏提取物以及尿液的分析表明发生了缓慢代谢。这些数据表明磷酸二酯寡核苷酸的治疗用途有限。硫代磷酸酯寡核苷酸的稳定性和器官分布表明此类寡核苷酸可能具有治疗潜力。

相似文献

1
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.体内3H标记寡核苷酸的生物分布与代谢。I. 磷酸二酯和硫代磷酸酯的比较。
Mol Pharmacol. 1994 May;45(5):932-43.
2
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.体内3H标记寡核苷酸的生物分布与代谢。II. 3',5'-封闭寡核苷酸。
Mol Pharmacol. 1995 Mar;47(3):636-46.
3
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.几种新型寡核苷酸类似物在小鼠体内的药代动力学特性
J Pharmacol Exp Ther. 1996 May;277(2):923-37.
4
Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.68Ga标记的磷酸二酯、硫代磷酸酯和2'-O-甲基磷酸二酯寡核苷酸在正常大鼠体内的生物分布。
Eur J Pharm Sci. 2005 Sep;26(1):26-38. doi: 10.1016/j.ejps.2005.04.017.
5
Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice.
J Pharmacol Exp Ther. 1996 Jan;276(1):326-34.
6
Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.G3139(一种针对bcl-2的硫代磷酸酯寡脱氧核苷酸反义药物)在对小鼠静脉注射或持续皮下输注后的药代动力学。
J Pharmacol Exp Ther. 1997 Apr;281(1):420-7.
7
Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.硫代磷酸反义寡脱氧核苷酸ISIS 3466在小鼠体内的药代动力学、组织分布及稳定性
Oncol Res. 1994;6(6):243-9.
8
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.一种C-raf-1激酶表达的硫代磷酸酯寡核苷酸反义抑制剂在小鼠体内的药代动力学和代谢情况。
Drug Metab Dispos. 1997 Nov;25(11):1272-81.
9
Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond.
Drug Metab Dispos. 1995 Nov;23(11):1297-300.
10
[Distribution of oligonucleotide derivatives and their stability in murine tissues].[寡核苷酸衍生物在小鼠组织中的分布及其稳定性]
Biokhimiia. 1993 Apr;58(4):590-8.

引用本文的文献

1
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies.基于核酸的疗法的进展与发展趋势
Biomolecules. 2025 Mar 5;15(3):376. doi: 10.3390/biom15030376.
2
Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy.T淋巴细胞中调节性免疫受体的可变剪接:一种新发现的且可靶向的抗癌免疫治疗机制。
Front Immunol. 2025 Jan 7;15:1490035. doi: 10.3389/fimmu.2024.1490035. eCollection 2024.
3
Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver.
寡核苷酸的代谢稳定性与靶向递送:推动RNA疗法超越肝脏应用。
J Med Chem. 2025 Apr 10;68(7):6870-6896. doi: 10.1021/acs.jmedchem.4c02528. Epub 2025 Jan 8.
4
Technologies for Targeted RNA Degradation and Induced RNA Decay.靶向RNA降解与诱导RNA衰变技术
Chem Rev. 2024 Dec 11;124(23):13301-13330. doi: 10.1021/acs.chemrev.4c00472. Epub 2024 Nov 5.
5
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.剪接调节反义寡核苷酸作为遗传性代谢疾病的治疗方法。
BioDrugs. 2024 Mar;38(2):177-203. doi: 10.1007/s40259-024-00644-7. Epub 2024 Jan 22.
6
RNA-based medicine: from molecular mechanisms to therapy.基于 RNA 的药物:从分子机制到治疗。
EMBO J. 2023 Nov 2;42(21):e114760. doi: 10.15252/embj.2023114760. Epub 2023 Sep 20.
7
Programming Cell-Derived Vesicles with Enhanced Immunomodulatory Properties.编程细胞衍生的囊泡,增强免疫调节性能。
Adv Healthc Mater. 2023 Oct;12(27):e2301163. doi: 10.1002/adhm.202301163. Epub 2023 Jul 9.
8
Drug Discovery Perspectives of Antisense Oligonucleotides.反义寡核苷酸的药物发现前景
Biomol Ther (Seoul). 2023 May 1;31(3):241-252. doi: 10.4062/biomolther.2023.001. Epub 2023 Mar 2.
9
Nucleic acid drug vectors for diagnosis and treatment of brain diseases.用于脑疾病诊断和治疗的核酸药物载体。
Signal Transduct Target Ther. 2023 Jan 17;8(1):39. doi: 10.1038/s41392-022-01298-z.
10
Clinical Pharmacokinetics of Approved RNA Therapeutics.已批准的 RNA 治疗药物的临床药代动力学。
Int J Mol Sci. 2023 Jan 1;24(1):746. doi: 10.3390/ijms24010746.